https://www.patientcareonline.com/view/tirzepatide-reduces-time-to-hba1c-targets-by-up-to-3-months-vs-semaglutide-insulin-degludec
0
0
9/15/22 at 6:12pm
Organization
Patientcareonline.com
Author
Grace Halsey
Tirzepatide in an exploratory analysis of SURPASS-2 and -3 trials added proof of shorter time to glycemic targets and weight loss goals to superior reduction of HbA1c.
Create an account
or login to join the discussion